The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer

The Impact of Carboplatin Dosing Design Using Adjusted Serum Creatinine on Carboplatin Plus Paclitaxel Therapy for Ovarian Cancer

ABSTRACT Background Carboplatin (CBDCA) is a mainstay of chemotherapy for ovarian cancer and its dose is determined in proportion to the estimated creatinine clearance (CCr). Serum creatinine (SCr) values necessary to estimate CCr vary by measurement method: adding 0.2 mg/dL to SCr by enzymatic meth...

Full description

Saved in:
Bibliographic Details
Main Authors: Shu Kato, Kaede Baba, Kanako Mamishin, Mao Uematsu, Mai Shimura, Akira Hirota, Misao Fukuda, Nobuyuki Takahashi, Takehiro Nakao, Hiromichi Nakajima, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Yoichi Naito, Nobuaki Matsubara, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Cancer Medicine
Subjects:
adjuvant chemotherapy
carboplatin
creatinine
ovarian cancer
paclitaxel
Online Access:https://doi.org/10.1002/cam4.70804
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items